EU Confirms Suspension Of 700 Generics But Indian Impact Unclear
This article was originally published in PharmAsia News
Executive Summary
An EU order to pull some 700 generic drug products off retail shelves over testing quality issues could cut India’s pharmaceutical annual exports by at least $1 billion, according to a government body, although there is some disagreement over the likely actual impact. The suspension has also fuelled fresh doubts about the standards followed by India's troubled clinical trials industry.